DEF: BioAge Labs Annual Meeting: Director Elections & Auditor Ratification

BioAge Labs, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 10, 2026, to elect directors and ratify KPMG LLP as its independent auditor.

Summary

• The company is holding its 2026 Annual Meeting of Stockholders virtually on June 10, 2026, at 12:00 p.m. Eastern Time.
• The primary purposes of the meeting are to elect three Class II directors for three-year terms and to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders of record as of April 16, 2026, are entitled to vote.
• Proxy materials are being furnished primarily over the internet, with a Notice of Internet Availability mailed on or about April 21, 2026.
• Voting can be done by mail, telephone, internet, or during the virtual meeting.
• The Board of Directors unanimously recommends a vote FOR the election of each director nominee and FOR the ratification of KPMG LLP.
• The company is an emerging growth company and a smaller reporting company, complying with reduced public company reporting requirements.
• Detailed information on corporate governance, director independence, board committees, executive compensation, and related party transactions is provided.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it focuses on routine corporate governance matters and director elections, indicating stable operations and adherence to regulatory requirements.

Positives

• The company is actively engaging stockholders through its annual meeting process.
• The Board of Directors is committed to good corporate governance practices.
• A clear separation of CEO and Chairperson roles is maintained, enhancing accountability and independence.
• Robust risk oversight is in place, with Board committees assisting in various risk areas, including cybersecurity.
• Director nominees possess extensive experience in life sciences, finance, and corporate governance.
• The company has adopted a Clawback Policy to comply with SEC regulations.
• The Audit Committee has reviewed and discussed the 2025 financial statements with management and KPMG LLP.
• The company has a policy for reviewing and approving related party transactions.

Negatives

• Two directors, Kristen Fortney, Ph.D. and Eric Morgen, M.D., are not considered independent.
• The filing does not contain specific financial performance metrics for the current period, as it is a proxy statement focused on governance and voting matters.

Risks

• Potential conflicts of interest for directors who are affiliated with investment firms that are significant stockholders.
• The company is an emerging growth company and a smaller reporting company, which may mean reduced disclosures compared to larger public companies.

Future Outlook

The filing is a proxy statement for the annual meeting and does not contain specific forward-looking financial guidance. It outlines proposals for director elections and auditor ratification, and provides information on corporate governance and executive compensation.

Management Comments

• "We are furnishing proxy materials to our stockholders over the Internet."
• "The attached notice and proxy statement describe the formal business to be transacted at the Annual Meeting."
• "Our Board of Directors has determined that the matters to be considered at the Annual Meeting are in the best interests of the Company and its stockholders."
• "For the reasons set forth in the Proxy Statement, the Board of Directors unanimously recommends a vote FOR each matter to be considered."
• "On behalf of the Board of Directors and the officers and employees of BioAge Labs, Inc., I would like to take this opportunity to thank our stockholders for their continued support of the Company."
• "We look forward to seeing you at the Annual Meeting."
• "We believe that a virtual stockholder meeting provides greater access to those who may want to attend, and therefore we have chosen this over an in-person meeting."
• "This process is designed to reduce our environmental impact and lower the costs of printing and distributing our proxy materials while providing our stockholders timely access to this important information."
• "Your vote as a BioAge Labs, Inc. stockholder is very important."
• "Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure that your vote is counted."

Industry Context

StockSavvy.ai notes that BioAge Labs, Inc., operating in the biotechnology sector, is following standard corporate governance practices by holding its annual meeting to elect directors and ratify its auditor. The virtual meeting format aligns with current trends in corporate communications, aiming for broader accessibility and cost efficiency.

Comparison to Industry Standards

• The election of directors by a plurality of votes cast is a standard practice in the biotechnology industry.
• The ratification of the independent registered public accounting firm is a common governance procedure across the industry.
• The structure of board committees (Audit, Compensation, Nominating and Governance) and their responsibilities are consistent with best practices in the life sciences sector.
• The compensation structure for non-employee directors, including cash retainers and equity awards, is typical for companies of this size and stage in the industry.

Corporate Governance

Related Party Transactions

• Entities affiliated with Cormorant purchased 1,250,000 shares of common stock for $24,375,000 in the January 2026 Public Offering.
• Various entities affiliated with directors and significant stockholders (Andreessen Horowitz, Cormorant, Longitude Venture Partners IV, L.P., Sofinnova Venture Partners XI, L.P., RA Capital, Khosla Ventures, Horsley Bridge) participated in the Series D Preferred Stock Financing in February 2024, purchasing an aggregate of approximately $170.0 million in Series D and Series D-1 Preferred Stock.
• Certain principal stockholders and their affiliated entities, including those affiliated with directors, purchased an aggregate of 1,827,777 shares of common stock for $32,899,986 in the initial public offering on September 26, 2024.
• Sofinnova Venture Partners XI, L.P., an affiliate of Dr. Healy, purchased approximately $10.6 million in shares of common stock in a concurrent private placement during the IPO.
• Lingling Chen, M.D., spouse of Dr. Eric Morgen, is employed by the Company in a non-executive officer position and received compensation of $487,095 in 2025 and $528,718 in 2024.

Stakeholder Impact

• Shareholders: The election of directors and ratification of the auditor directly impact corporate governance and oversight, influencing shareholder confidence and long-term value.
• Employees: The company's corporate governance and executive compensation policies, as detailed in the filing, can influence employee morale and retention.
• Directors and Officers: The filing details their compensation, equity holdings, and severance arrangements, providing transparency to stakeholders.
• Investors: Information on beneficial ownership and related party transactions provides insights into the company's ownership structure and potential conflicts of interest.

Next Steps

• Stockholders to vote on the election of Class II directors.
• Stockholders to ratify the appointment of KPMG LLP as the independent registered public accounting firm.
• The company will hold its 2026 Annual Meeting of Stockholders virtually on June 10, 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, focusing on corporate governance, director elections, and auditor ratification. It does not contain new financial performance data or strategic updates that would warrant a buy or sell recommendation. The information presented is standard for such filings and indicates the company is operating under established governance procedures.

Keywords

BioAge Labs, DEF 14A, Proxy Statement, Annual Meeting, Stockholders, Board of Directors, Director Election, KPMG LLP, Independent Auditor, Corporate Governance, Executive Compensation, Related Party Transactions